Prognostic immune markers in esophageal cancer patients managed with trimodal therapy

Abstract Background Esophageal cancer (ESC) is an aggressive disease which often presents at an advanced stage. Despite trimodal therapy, 40–50% patients can develop metastatic disease by 18 months. Identification of patients at risk for metastatic spread is challenging with need for improved progno...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark K. Farrugia, Elizabeth A. Repasky, Minhui Chen, Kristopher Attwood, Kayla Catalfamo, Hanna Rosenheck, Song Yao, David M. Mattson, Sarbajit Mukherjee, Moshim Kukar, Agnieszka K. Witkiewicz, Anurag K. Singh
Format: Article
Language:English
Published: Springer 2025-01-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Online Access:https://doi.org/10.1007/s00262-024-03891-3
Tags: Add Tag
No Tags, Be the first to tag this record!